› Forums › General Melanoma Community › Does Dabrafenib Plus Trametinib Offer Survival Benefits
- This topic has 6 replies, 5 voices, and was last updated 5 years, 8 months ago by
Bubbles.
- Post
-
- September 6, 2019 at 3:35 pm
Viewing 3 reply threads
- Replies
-
-
- September 6, 2019 at 7:20 pm
Anon, you might want to include some of the data coming out of the newest targeted therapy combination Encorafenib/Binimetinib, kind of making dab/tram look bad!!! https://www.onclive.com/web-exclusives/encorafenib-binimetinib-combo-continues-to-show-survival-benefit-in-braf-mutant-melanoma-
- September 6, 2019 at 7:21 pm
Here is the dab/tram data to compare to Encorafenib/Binimetinib. https://www.nejm.org/doi/full/10.1056/NEJMoa1904059 -
- September 7, 2019 at 3:05 am
I was wondering if anyone else had noticed that on the Columbus trial, around week 27 almost everyone on encorafenib+ bininmetanib progressed while the earlier generations of braf/mek drugs seem to suggest that 20-30% of people stopped progressing/never had their cancer return? Do you think this was just a fluke or that the earlier generation Braf/mek can stop the cancer for 20-30% even if the overall PFS is less? Or am I reading the charts wrong? Page 7 on the link below.
https://www.researchgate.net/publication/323942346_Encorafenib_plus_binimetinib_versus_vemurafenib_or_encorafenib_in_patients_with_BRAF_-mutant_melanoma_COLUMBUS_a_multicentre_open-label_randomised_phase_3_trial
-
- September 6, 2019 at 7:59 pm
I am here to answer this YES! I went from stage 3 to stage 4 with 2 brain mets. I immediately started the Dabrafenib/Trametinib combo and did SRS. Seven months later my brain mets had resolved. I stayed on the combo for a full 2 years. This October will be my 3 yr anniversary of being NED. A complete, long term response can happen. (I’m cautiously optimistic about the long term part)
My Oncologist at MD Anderson was on the study for the two new BRAF+ drugs and she was Extremely excited about them. Less adverse effects and no fasting involved are two very big pluses besides the efficacy.
I may be an outlier but I had low tumor burden and normal LDH going for me. -
- September 6, 2019 at 9:02 pm
In comparison to what? To chemotherapy or vemurafenib alone – yes. In comparison to immune checkpoint inhibitors, we do not know. Sadly, the randomized head to head clinical trial of these treatments is unlikely to ever be done (or at least not soon), so we will continue to not know. -
- September 8, 2019 at 12:42 pm
Melanoma is never simple and clinical trials are rarely set up as I would run them!! HA! Both huge understatements, right? Here’s my take on the Columbus trial and links to additional data for targeted therapy: https://chaoticallypreciselifeloveandmelanoma.blogspot.com/2018/03/encorafenib-plus-binimetinib-better.htmlFor what it’s worth.
And while it is true that for many (if BRAF positive) targeted therapy provides a miraculous response though often with limited durability. However, there are some for whom it is an amazing long term fix. Richard_K is one!! https://melanoma.org/legacy/find-support/patient-community/mpip-melanoma-patients-information-page/vemurafenib-question
Best wishes to you all. celeste
-
Viewing 3 reply threads
- You must be logged in to reply to this topic.